Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Acorda Therapeutics (ACOR) stock in Canada

Own Acorda Therapeutics (ACOR) shares in just a few minutes.

Acorda Therapeutics (ACOR) (ACOR) is a leading drug manufacturers-specialty & generic business based in the US. It opened the day at $5.16 after a previous close of $5.19. During the day the price has varied from a low of $5.1046 to a high of $5.28. The latest price was $5.23 (25 minute delay). Acorda Therapeutics (ACOR) is listed on the NASDAQ and employs 167 staff. All prices are listed in US Dollars.

How to buy shares in Acorda Therapeutics (ACOR)

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ACOR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Acorda Therapeutics (ACOR) stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Acorda Therapeutics (ACOR)'s stock price?

Since the stock market crash in March caused by coronavirus, Acorda Therapeutics (ACOR)'s stock price has had significant positive movement.

Its last market close was $2.16, which is 29.63% up on its pre-crash value of $1.52 and 208.53% up on the lowest point reached during the March crash when the stocks fell as low as $0.7001.

If you had bought $1,000 worth of Acorda Therapeutics (ACOR) stocks at the start of February 2020, those stocks would have been worth $430.25 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,064.04.

Acorda Therapeutics (ACOR) stock price (NASDAQ:ACOR)

Use our graph to track the performance of ACOR stocks over time.

Acorda Therapeutics (ACOR) shares at a glance

Information last updated 2021-06-28.
Previous close$5.19
Change $0.04
Change % 0.7707%
Volume 194,057
Information last updated 2022-01-17.
52-week range$2.13 - $8.66
50-day moving average $2.80
200-day moving average $3.90
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-17.04

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Acorda Therapeutics (ACOR) price performance over time

Historical closes compared with the close of $5.23 from 2022-01-14

1 week (2022-01-07) N/A
1 month (2021-12-16) 104.30%
3 months (2021-10-14) N/A
6 months (2021-07-16) 41.73%
1 year (2021-01-15) -21.94%
2 years (2020-01-17) 152.66%
3 years (2019-01-18) 16.26
5 years (2017-01-18) 21.1

Is Acorda Therapeutics (ACOR) under- or over-valued?

Valuing Acorda Therapeutics (ACOR) stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acorda Therapeutics (ACOR)'s overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Acorda Therapeutics (ACOR)'s PEG ratio

Acorda Therapeutics (ACOR)'s "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics (ACOR)'s future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Acorda Therapeutics (ACOR) financials

Revenue TTM $130.3 million
Gross profit TTM $96.8 million
Return on assets TTM -9.05%
Return on equity TTM -69.64%
Profit margin -127.77%
Book value $14.70
Market capitalisation $24.2 million

TTM: trailing 12 months

Acorda Therapeutics (ACOR) share dividends

We're not expecting Acorda Therapeutics (ACOR) to pay a dividend over the next 12 months.

Have Acorda Therapeutics (ACOR)'s shares ever split?

Acorda Therapeutics (ACOR)'s shares were split on a 1:6 basis on 4 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics (ACOR) shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Acorda Therapeutics (ACOR) shares which in turn could have impacted Acorda Therapeutics (ACOR)'s share price.

Acorda Therapeutics (ACOR) share price volatility

Over the last 12 months, Acorda Therapeutics (ACOR)'s shares have ranged in value from as little as $2.13 up to $8.66. A popular way to gauge a stock's volatility is its "beta".

ACOR.US volatility(beta: 0.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics (ACOR)'s is 0.5003. This would suggest that Acorda Therapeutics (ACOR)'s shares are less volatile than average (for this exchange).

Acorda Therapeutics (ACOR) overview

Acorda Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.

Stocks similar to Acorda Therapeutics (ACOR)

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site